1. Home
  2. MUC vs ANNX Comparison

MUC vs ANNX Comparison

Compare MUC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniHoldings California Quality Fund Inc.

MUC

Blackrock MuniHoldings California Quality Fund Inc.

HOLD

Current Price

$10.54

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.96

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUC
ANNX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
972.5M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
MUC
ANNX
Price
$10.54
$4.96
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
231.1K
1.8M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.00
$1.85
52 Week High
$11.04
$7.18

Technical Indicators

Market Signals
Indicator
MUC
ANNX
Relative Strength Index (RSI) 30.98 30.95
Support Level $10.20 $4.79
Resistance Level $10.90 $5.07
Average True Range (ATR) 0.06 0.29
MACD -0.03 -0.09
Stochastic Oscillator 5.41 3.90

Price Performance

Historical Comparison
MUC
ANNX

About MUC Blackrock MuniHoldings California Quality Fund Inc.

BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: